跳转至内容
Merck
CN

SML4054

Sigma-Aldrich

AFQ056

≥98% (HPLC)

别名:

(3aR,4S,7aR)-Octahydro-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-1H-indole-1-carboxylic acid methyl ester, AFQ 056, Mavoglurant

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C19H23NO3
化学文摘社编号:
分子量:
313.39
MDL编号:
UNSPSC代码:
12352200
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

质量水平

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

-10 to -25°C

SMILES字符串

O[C@]1(C#CC2=CC(C)=CC=C2)[C@@]3([H])[C@@](N(C(OC)=O)CC3)([H])CCC1

InChI key

ZFPZEYHRWGMJCV-ZHALLVOQSA-N

生化/生理作用

Orally active, potent and selective mGluR5 antagonist.

AFQ056 (Mavoglurant) is an orally active, potent and selective antagonist of metabotropic glutamate receptor 5 (mGluR5). AFQ056 was investigated for treatment of fragile X syndrome and for Parkinson′s disease.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Sébastien Jacquemont et al.
Science translational medicine, 3(64), 64ra1-64ra1 (2011-01-07)
Fragile X syndrome (FXS) is an X-linked condition associated with intellectual disability and behavioral problems. It is caused by expansion of a CGG repeat in the 5' untranslated region of the fragile X mental retardation 1 (FMR1) gene. This mutation
Laurent Grégoire et al.
Parkinsonism & related disorders, 17(4), 270-276 (2011-02-15)
Overactivity of glutamatergic transmission has been implicated in Parkinson's disease (PD) and levodopa (L-Dopa)-induced dyskinesias. Striatal metabotropic glutamate receptors type 5 (mGluR5) are abundant and provide specific targets to modulate glutamatergic activity. This study investigated the acute effects of the
Kirstie A Bennett et al.
The Journal of pharmacology and experimental therapeutics, 377(1), 157-168 (2021-02-06)
The metabotropic glutamate receptor 5 (mGlu5) is a recognized central nervous system therapeutic target for which several negative allosteric modulator (NAM) drug candidates have or are continuing to be investigated for various disease indications in clinical development. Direct measurement of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持